2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Multiple Myeloma
11
Lymphoma, Non-Hodgkin
9
Lymphoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Leukemia, Myeloid, Acute
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hodgkin Disease
5
Myelodysplastic Syndromes
4
Neoplasms, Plasma Cell
3
Melanoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Primary Myelofibrosis
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Lymphoma, B-Cell
2
Immunoglobulin Light-chain Amyloidosis
2
Hematologic Neoplasms
2
Glioblastoma
2
Burkitt Lymphoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Philadelphia Chromosome
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Interventions
Cisplatin
57
Pemetrexed
46
pembrolizumab
18
Nivolumab
15
Carboplatin
15
Gemcitabine
14
Cyclophosphamide
13
Radiotherapy
10
Drug Therapy
9
atezolizumab
8
Platinum
7
Ipilimumab
7
Doxorubicin
7
durvalumab
6
1,2-diaminocyclohexaneplatinum II citrate
6
tremelimumab
5
sodium thiosulfate
5
Vinorelbine
5
Radiotherapy, Intensity-Modulated
5
Interleukin-2
5
Chemotherapy, Adjuvant
5
Cerebral Decortication
5
sargramostim
4
fludarabine
4
defactinib
4
aldesleukin
4
tumor necrosis factor-alpha, CNGRC fusion protein, human
3
cediranib
3
Photochemotherapy
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Blood Component Removal
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled